Private company

Immudex

Immudex is a Danish Reagents and Diagnostics company established in 2009. The company is operating from offices located in Copenhagen, Denmark, and in Fairfax, Virginia. Immudex specializes in the production of MHC Dextramers.2 Wikipedia text CC BY-SA 4.0

Last updated Oct 21, 2026.

Overview

2009Founded1

Immudex is a Danish Reagents and Diagnostics company established in 2009. The company is operating from offices located in Copenhagen, Denmark, and in Fairfax, Virginia. Immudex specializes in the production of MHC Dextramers. MHC Dextramers are chemical reagents that are designed to detect antigen-specific T cells.2

The story

Originally, Immudex operated as an individual division within the much larger Danish pharmaceutical company Dako. Immudex was later spun out as a separate business, when the focus of Dako largely shifted to cancer diagnostics. Immudex currently have clients world wide with major markets in the United States and Europe.

Patents for the MHC Dextramer technology were filed at Dako in 2001, and the Immudex division was launched in 2005.

In 2011, Immudex received the prestigious “Entrepreneur of the Year 2011” award in the Life Sciences category granted by Ernst & Young.

Immudex received this award because of the commitment of the company, articulated in the company's "make it work and make it better" strategy to generate results for both practitioners and patients. The award is given to companies not only focused on financial growth, but also for softer values such as the entrepreneur's social responsibility and the ability to aspire an motivate the organization.

From Wikipedia’s article on Immudex, shared under CC BY-SA 4.0.3

Products and brands

Dextramer technology

A large number of immunotherapies, currently in development, seek to induce, expand, activate or eliminate antigen-specific T cells. It is therefore important to be able to quantify and characterize the T cell responses before, during and after treatment in order to understand if the proposed change to the T cells has been effectuated.

The process of negative selection in the thymus guarantees that virtually all T cells have very weak affinity for self-antigens. Therefore, the study of these lymphocytes in autoimmune diseases and cancer has been difficult, until the fairly recent introduction of MHC multimers. Tetramers, which are among the most popular form of these multimer complexes, have four binding sites. The Tetramers were originally developed in Academia. Many further developments in this technology have taken place at biotechnology companies.

The Immudex MHC Dextramers, which represent the latest advancement in this field, provide an exponentially greater probability of successful identification of antigen-specific T cells. This can be done, because the MHC Dextramers have nine, or more binding sites per dextran backbone. Scientists have been optimistic about the potential of such technology, since it will help broaden the understanding of T cell responses and will in the future be clinically applicable to many different antigen-specific T cells.

Products

The MHC Dextramers are fluorescent MHC multimer reagents, developed for sensitive, specific and accurate detection of antigen-specific T cells by using Flow cytometry. The MHC Dextramers covers human, mouse, and monkey alleles that all display disease relevant antigenic peptides. The MHC Dextramers can thereby be used for monitoring antigen-specific T cell responses.

Read the full text

Virus Dextramer collection 1 - provides reagents for detection, quantification and isolation of virus specific T cells. It furthermore enables detection for CMV-, EBV-, influenza-, and BK virus specific CD8+ T cells.

Dextramer CMV kit - These MHC Dextramers provide a method for quantification of CMV-specific CD8+ T cells in whole blood samples as an aid in predicting and monitoring patients at risk of developing CMV-related disease.

Melanoma Dextramer collection 1 - comprises MHC Dextramers specific for 6 different melanoma-associated antigens and can be used for the detection, enumeration and isolation of melanoma-specific CD8+ T cells from blood or tumor tissue.

Cancer Testis Antigen CD1d Dextramer - These MHC Dextramers are flow cytometry reagents for the identification and sorting of Natural killer cells (NKT), as well as an extensive range of single reagents for detection of cancer- and viral-specific T cells. The CD1d/α-GalCer displays human CD1d molecules loaded with α-GalCer.

From Wikipedia’s article on Immudex, shared under CC BY-SA 4.0.3

Timeline

  1. 2009Founded Founded1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3